CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Tacrolimus Modified Release (MR) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00282568
NCT00282568Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Safety and Tolerability of Tacrolimus in Stable Kidney Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen

Astellas Pharma Inc·interventional·Posted Jan 27, 2006·Updated Sep 26, 2013

In Brief

A Phase 2 clinical trial evaluating Tacrolimus Modified Release (MR) and tacrolimus for Kidney Transplantation. Completed, enrolled 70 participants across 9 sites in 2 countries.

Detailed Summary

A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable kidney transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based immunosuppression regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2006
Enrollment StartAug 1, 2002
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 20.4 years ago

Interventions

Tacrolimus Modified Release (MR)drug

Oral

tacrolimusdrug

Oral